A phase II study of ramucirumab for advanced, pre-treated biliary cancers.

被引：2
|
作者：
Mizrahi, Jonathan
Javle, Milind M.
Xiao, Lianchun
Varadhachary, Gauri R.
Raghav, Kanwal Pratap Singh
Wolff, Robert A.
Shroff, Rachna T.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept GI Med Oncol, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4081
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4081
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A Phase II Study to Determine the Efficacy and Safety of Oral Treosulfan in Patients With Advanced Pre-Treated Ewing Sarcoma ISRCTN11631773
    Michelagnoli, M.
    Whelan, J.
    Forsyth, S.
    PEDIATRIC BLOOD & CANCER, 2015, 62 (01) : 158 - 159
  • [32] Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone
    Paz-Ares, Luis
    Lopez-Pousa, Antonio
    Poveda, Andres
    Balana, Carmen
    Ciruelos, Eva
    Bellmunt, Joaquim
    Garcia del Muro, Javier
    Provencio, Mariano
    Casado, Antonio
    Rivera-Herrero, Fernando
    Izquierdo, Miguel Angel
    Nieto, Antonio
    Tanovic, Adnan
    Cortes-Funes, Hernan
    Maria Buesa, Jose
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 729 - 740
  • [33] Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers
    Afshin Dowlati
    James Posey
    Ramesh K. Ramanathan
    Linda Rath
    Pingfu Fu
    Amitabh Chak
    Smitha Krishnamurthi
    Joanna Brell
    Stephen Ingalls
    Charles L. Hoppel
    Percy Ivy
    Scot C. Remick
    Cancer Chemotherapy and Pharmacology, 2009, 65 : 73 - 78
  • [34] Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone
    Luis Paz-Ares
    Antonio López-Pousa
    Andrés Poveda
    Carmen Balañá
    Eva Ciruelos
    Joaquim Bellmunt
    Javier García del Muro
    Mariano Provencio
    Antonio Casado
    Fernando Rivera-Herrero
    Miguel Ángel Izquierdo
    Antonio Nieto
    Adnan Tanović
    Hernán Cortes-Funes
    José María Buesa
    Investigational New Drugs, 2012, 30 : 729 - 740
  • [35] Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers
    Dowlati, Afshin
    Posey, James
    Ramanathan, Ramesh K.
    Rath, Linda
    Fu, Pingfu
    Chak, Amitabh
    Krishnamurthi, Smitha
    Brell, Joanna
    Ingalls, Stephen
    Hoppel, Charles L.
    Ivy, Percy
    Remick, Scot C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 65 (01) : 73 - 78
  • [36] Outcomes of second line treatment in patients with advanced and metastatic biliary cancers.
    Westin, Gustavo Figueiredo Marcondes
    Alsidawi, Samer
    Chandrasekharan, Chandrikha
    Briggler, Andrew M.
    Huffman, Brendon
    Pallante, Angeline
    Hubbard, Joleen Marie
    Alberts, Steven R.
    Halfdanarson, Thorvardur Ragnar
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [37] Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study
    Park, JS
    Oh, SY
    Kim, SH
    Kwon, HC
    Kim, JS
    Hyo, JK
    Kim, YH
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (02) : 68 - 73
  • [38] Combination immunotherapy with ipilimumab and nivolumab in patients with advanced biliary tract cancers.
    Klein, Oliver
    Kee, Damien
    Nagrial, Adnan
    Ben Markman
    Underhill, Craig
    Michael, Michael
    Lum, Caroline
    Behren, Andreas
    Palmer, Jodie
    Tebbutt, Niall C.
    Carlino, Matteo S.
    Cebon, Jonathan S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Updated results from the phase II study: Efficacy and safety of anlotinib plus sintilimab as second-line treatment for patients with advanced biliary tract cancers.
    Jin, Shuiling
    Zhao, Ruihua
    Zhou, Chuang
    Zhong, Qian
    Zhang, Xiaojian
    Zong, Hong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 577 - 577
  • [40] Phase I-II trial of concomitant pre-operative hyperfractionated radiotherapy and gemcitabine for locally advanced rectal cancers.
    Allal, AS
    Bieri, S
    Gervaz, P
    Soravia, C
    Gertsch, P
    Morel, P
    Roth, AD
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 288S - 288S
12345